Medpace Holdings, Inc. $MEDP Stock: Illinois Municipal Retirement Fund Boosts Stake

Illinois Municipal Retirement Fund raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 31.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,652 shares of the company’s stock after acquiring an additional 2,061 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Medpace were worth $5,400,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Johnson Financial Group Inc. acquired a new position in Medpace in the second quarter valued at about $27,000. Jones Financial Companies Lllp bought a new stake in Medpace during the second quarter worth about $30,000. Allied Private Wealth LLC bought a new stake in Medpace during the second quarter worth about $31,000. Kilter Group LLC acquired a new stake in shares of Medpace during the second quarter worth approximately $31,000. Finally, Basecamp Wealth Advisors LLC increased its holdings in shares of Medpace by 187.5% during the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after buying an additional 45 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $653.94 on Monday. The stock has a market cap of $18.29 billion, a price-to-earnings ratio of 36.25, a P/E/G ratio of 2.54 and a beta of 1.12. The company has a 50 day moving average of $629.52 and a 200-day moving average of $533.79. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $693.97.

Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The company reported $4.84 EPS for the quarter, beating analysts’ consensus estimates of $4.44 by $0.40. The business had revenue of $716.00 million during the quarter, compared to the consensus estimate of $714.47 million. Medpace had a return on equity of 99.76% and a net margin of 18.24%. The firm’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.86 earnings per share. Equities research analysts anticipate that Medpace Holdings, Inc. will post 18.06 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on MEDP. Truist Financial increased their price target on Medpace from $609.00 to $633.00 and gave the stock a “hold” rating in a research report on Friday, October 23rd. TD Cowen raised their price target on Medpace from $492.00 to $673.00 and gave the company a “hold” rating in a report on Friday, October 23rd. Mizuho set a $730.00 price objective on Medpace in a research report on Friday, October 23rd. Leerink Partners set a $620.00 price objective on Medpace in a research note on Thursday, July 23rd. Finally, Weiss Ratings upgraded Medpace from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $649.27.

View Our Latest Stock Report on MEDP

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 49,018 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the completion of the transaction, the chief executive officer owned 433,372 shares of the company’s stock, valued at $272,205,286.92. This represents a 10.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Susan E. Burwig sold 16,060 shares of the firm’s stock in a transaction on Monday, October 26th. The shares were sold at an average price of $677.00, for a total transaction of $10,872,620.00. Following the completion of the transaction, the vice president directly owned 57,624 shares of the company’s stock, valued at approximately $39,011,448. This trade represents a 21.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 306,539 shares of company stock worth $191,774,429. Insiders own 20.50% of the company’s stock.

Medpace Profile

(Free Report)

Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas. Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.

Further Reading

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.